The interstitial lung diseases (ILDs) include a wide variety of relatively uncommon disorders. Technologic advances in sequencing and genotyping have led to an explosion of genetic discoveries, shedding new light on the underlying pathogenesis of ILD. New monogenic syndromes have been described, often with clinically diverse and extreme phenotypes, based on the discovery of single gene mutations. In addition, many apparently disparate clinical presentations have been linked together through the discovery of mutations in the same gene or mutations in multiple genes sharing a common pathway. These genetic discoveries have only further increased the number of discrete ILDs. The genetic etiology provides a molecular framework for the disease and provides patients and their treating physicians with an explanation of phenotypes that are often seen across multiple organs. As more cohorts of patients are described with these rare syndromes, more information will be gleaned about the natural history of disease and best practices for surveillance and treatment. The goal of this chapter is to summarize (1) genetic syndromes involving multiple organs, in which ILD is one of many different phenotypes, and (2) genetic disorders in which ILD is the dominant phenotype.
As a rule, manifestations of ILD even within a single gene syndrome are generally characterized by a spectrum of clinical presentations, a wide range in age of onset, and incomplete penetrance. Thus, a high level of suspicion is needed for many of these disorders. Detecting a pattern of inheritance in large, extended kindreds across multiple generations separated by time and space strongly supports a genetic mechanism of disease. A detailed family history also provides important information about personal and family member phenotypes, providing important clues that may suggest a certain genetic diagnosis. For example, a personal or family history of bone marrow failure, early graying, or liver disease in a patient with adult-onset pulmonary fibrosis suggests a short telomere syndrome. Younger and more severely affected individuals in later generations may reflect genetic anticipation, which can also be seen in short telomere syndromes. Some diseases show a predisposition for affecting a certain gender, for example, affected males and asymptomatic carrier females suggest an X-linked disorder.
All ILDs arise from the infiltration of inflammatory and fibrotic mediators into the lung parenchyma. Very few cells normally reside within the interstitium, which is the delicate space between the alveolar epithelial cells and the capillary vascular endothelial cells. The filling of the interstitial space with inflammatory cells, activated fibroblasts, and extracellular matrix causes irreversible architectural distortion and impairs gas exchange. Most ILDs share similar clinical signs and symptoms, including respiratory distress and cough. Pulmonary restriction and a decreased diffusion capacity are frequently found, as well as radiographic evidence of parenchymal abnormalities. However, the radiographic and histopathologic features of ILDs vary widely. Historically, the type of infiltrating cells, the pattern of infiltration (nodular, reticular, alveolar), the nature of extracellular protein deposits (collagen, elastin, periodic acidâSchiff [PAS]-positive), the location of abnormalities (peripheral, alveolar, peribronchiolar), the pattern of the fibrotic response (fibroblastic foci, temporal/spatial homogeneity, or heterogeneity), and the form of lung destruction (cysts, bronchiectasis, honeycombing) have been used to describe different clinical forms of ILD. Now that genetic underpinnings of some monogenic ILDs are being established, classification by genetic etiology may ultimately supplant historical classification schemes. This will occur most readily for those disorders in which the genetic classification predicts specific treatments (e.g., sirolimus for tuberous sclerosis complex [TSC]âlymphangioleiomyomatosis [LAM]). A genetic classification of ILD is also advisable for those diseases in which the genetic information provides information relevant to patient care. For example, regular screening may lead to earlier interventions to remove premalignant renal cancers in patients with Birt-Hogg-DubĂŠ syndrome (BHDS). Similarly, knowledge of a monogenic short telomere syndrome provides prognostic information regarding the rate of ILD progression and the nature of specific postâlung transplant complications.
In this chapter, I focus primarily on disorders caused by rare mutations and include selected common variants that significantly increase susceptibility to ILD. The nomenclature of diseases follows the genetic classification system adopted by the Online Mendelian Inheritance in Man (http://www.omim.org). Other pulmonary genetic diseases are not covered. I refer to other excellent resources for reviews of alpha-1-antitrypsin deficiency, cystic fibrosis and CFTR-related disorders, primary ciliary dyskinesia, pulmonary capillary or venoocclusive disease, pulmonary malformation syndromes, and disorders that primarily affect the thoracic ...